Twitter
Advertisement

Glenmark gets USFDA nod for multiple sclerosis medication

Glenmark Pharmaceuticals on Thursday said it has received approval from the US health regulator for Teriflunomide tablets used to treat multiple sclerosis.

Latest News
article-main
FacebookTwitterWhatsappLinkedin

Glenmark Pharmaceuticals on Thursday said it has received approval from the US health regulator for Teriflunomide tablets used to treat multiple sclerosis.

The approved product is generic version of Sanofi-Aventis US' Aubagio.

Glenmark Pharmaceuticals, USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Teriflunomide tablets in the strengths of 7 mg and 14 mg, the company said in a BSE filing.

Glenmark said with respect to 180-day generic drug exclusivity, it was one of the applicants to submit a substantially complete first abbreviated new drug application (ANDA) for Teriflunomide tablets.

"Therefore, with this approval, Glenmark is eligible for 180 days of shared generic drug exclusivity for Teriflunomide Tablets, 7 mg and 14 mg," it added.

Citing IQVIA sales data for the 12-month period ending September 2018, the company said the Aubagio tablets market achieved annual sales of approximately USD 1.6 billion.

The company's current portfolio consists of 142 products authorised for distribution at the US marketplace and 57 Abbreviated New Drug Applications (ANDAs) pending approval with the USFDA.

The company's stock was trading at Rs 658.75 apiece, down 0.86 per cent, on the BSE.

Earlier, Glenmark Pharmaceuticals had won a trademark battle in the Bombay High Court, against a lookalike brand, which sold dusting powder by the name 'Candidat'.

Justice SJ Kathawala, while restraining further sale of the lookalike brand being sold by Curewell Drugs and Pharmaceuticals, ordered the court receiver to seize all the manufactured good of the company and also pay Rs 35 lakh to Glenmark.

Advocate Hiren Kamod and Advocate MA Mahadgut, who appeared for Glenmark, argued before the court: "In 2014, the company started using unique and artistic packaging label and has been using the label continuously and extensively. In April this year, it came across the defendants brand of Candidat, which has copied each and every element of the Candid trademark."

Find your daily dose of news & explainers in your WhatsApp. Stay updated, Stay informed-  Follow DNA on WhatsApp.
Advertisement

Live tv

Advertisement
Advertisement